



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/674,311	07/01/1996	OLUFUNMILAYO I. OLOPADE	ARSB:509	8112

7590 10/22/2003

DAVID L. PARKER  
FULBRIGHT & JAWORSKI LLP  
600 CONGRESS AVENUE  
SUITE 2400  
AUSTIN, TX 78701

EXAMINER
----------

GOLDBERG, JEANINE ANNE

ART UNIT	PAPER NUMBER
----------	--------------

1634

DATE MAILED: 10/22/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Response to Rule 312 Communication</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	08/674,311	OLOPADE, OLUFUNMILAYO I.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Jeanine A Goldberg	1634	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

1. ☒ The amendment filed on 04 August 2003 under 37 CFR 1.312 has been considered, and has been:

a) ☐ entered.

b) ☐ entered as directed to matters of form not affecting the scope of the invention.

c) ☐ disapproved because the amendment was filed after the payment of the issue fee.

Any amendment filed after the date the issue fee is paid must be accompanied by a petition under 37 CFR 1.313(c)(1) and the required fee to withdraw the application from issue.

d) ☐ disapproved. See explanation below.

e) ☒ entered in part. See explanation below.

The response amends figure 19B to remove the restriction enzyme map at the bottom of the figure. The examiner also noticed that the headings for each of the subfigures was changed. In a conversation with Monica De La Paz, the examiner explained that either the figure legend was now incorrect or the newly submitted figure was incorrect. The newly submitted figures and the figures of record appear to be the same, therefore, changing the "probe" designation on the top caused inconsistencies. Moreover, the probe names are specific to the individual restriction enzyme fragments. The response provides no information or explanation directed to the new heading probe names. The examiner invited the applicant to file a new copy of Figure 19B which has been entered into the application (paper filed 9/16/03).

*J. Goldberg*

*Gary Ben Zion*  
 GARY BENZION, PH.D.  
 SUPERVISORY PATENT EXAMINER  
 TECHNOLOGY CENTER 1600